These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 34431250)

  • 41. Pre- and post- operative adjuvant targeting locoregional chemotherapy combined with locoregional targeting immunostimulation and surgical resection for hepatocellular carcinoma. A new promising alternative.
    Lygidakis NJ; Konstantinidou T; Pothoulakis J
    Anticancer Res; 1994; 14(3B):1351-5. PubMed ID: 8067704
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma.
    Meng M; Li W; Yang X; Huang G; Wei Z; Ni Y; Han X; Wang J; Ye X
    J Cancer Res Ther; 2020; 16(2):327-334. PubMed ID: 32474520
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment.
    Tsochatzis EA; Germani G; Burroughs AK
    Semin Oncol; 2010 Apr; 37(2):89-93. PubMed ID: 20494700
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Goals and targets for personalized therapy for HCC.
    Couri T; Pillai A
    Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expanding TACTICS trial into a different setting in hepatocellular carcinoma.
    da Fonseca L; Carrilho FJ
    Ann Hepatol; 2020; 19(3):230-231. PubMed ID: 32139261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interventional treatment for unresectable hepatocellular carcinoma.
    Murata S; Mine T; Sugihara F; Yasui D; Yamaguchi H; Ueda T; Onozawa S; Kumita S
    World J Gastroenterol; 2014 Oct; 20(37):13453-65. PubMed ID: 25309076
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of Hepatocellular Carcinoma: Current Status and Future Directions.
    Au JS; Frenette CT
    Gut Liver; 2015 Jul; 9(4):437-48. PubMed ID: 26087860
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [State of the art in the diagnostics of hepatocellular carcinoma and current treatment options].
    Ringe KI; Hinrichs JB
    Radiologe; 2021 Feb; 61(2):213-226. PubMed ID: 33464405
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent developments with immunotherapy for hepatocellular carcinoma.
    Waidmann O
    Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).
    Kudo M; Arizumi T
    Oncology; 2017; 93 Suppl 1():127-134. PubMed ID: 29258086
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?
    Celsa C; Cabibbo G; Enea M; Battaglia S; Rizzo GEM; Busacca A; Giuffrida P; Stornello C; Brancatelli G; Cannella R; Gruttadauria S; Cammà C
    Liver Int; 2021 May; 41(5):1105-1116. PubMed ID: 33587814
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
    Salem R; Lewandowski RJ; Kulik L; Wang E; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Ibrahim SM; Senthilnathan S; Baker T; Gates VL; Atassi B; Newman S; Memon K; Chen R; Vogelzang RL; Nemcek AA; Resnick SA; Chrisman HB; Carr J; Omary RA; Abecassis M; Benson AB; Mulcahy MF
    Gastroenterology; 2011 Feb; 140(2):497-507.e2. PubMed ID: 21044630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis.
    Miura JT; Gamblin TC
    Surg Oncol Clin N Am; 2015 Jan; 24(1):149-66. PubMed ID: 25444473
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
    Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
    BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.
    Poon RT; Fan ST; Tsang FH; Wong J
    Ann Surg; 2002 Apr; 235(4):466-86. PubMed ID: 11923602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transcatheter chemoembolization of unresectable hepatocellular carcinoma: current knowledge and future directions.
    Maleux G; van Malenstein H; Vandecaveye V; Heye S; Vaninbroukx J; Nevens F; Verslype C
    Dig Dis; 2009; 27(2):157-63. PubMed ID: 19546554
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
    Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
    Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic advances for patients with intermediate hepatocellular carcinoma.
    Sun JY; Yin T; Zhang XY; Lu XJ
    J Cell Physiol; 2019 Aug; 234(8):12116-12121. PubMed ID: 30648254
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma.
    Tsochatzis EA; Fatourou E; O'Beirne J; Meyer T; Burroughs AK
    World J Gastroenterol; 2014 Mar; 20(12):3069-77. PubMed ID: 24695579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
    Eggert T; Greten TF
    Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.